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TESTING FOR ANEMIA
BACKGROUND
In any individual, anemia may be the initial laboratory sign
of an underlying medical problem. Consequently, a complete
blood count, including the hemoglobin (Hb) concentration,
is routinely part of global health assessment in most adults,
whether or not they have chronic kidney disease (CKD). In
patients with CKD but stable kidney function, the appear-
ance or progression of anemia may herald a new problem
that is causing blood loss or is interfering with red cell
production. The anemia should be evaluated independently
of CKD stage in order to identify any reversible process
contributing to the anemia. The causes of acquired anemia
are myriad and too many to include in a guideline such as
this. A comprehensive list of causes and the approach to
diagnosis can be found in a standard textbook of medicine or
hematology. The most commonly encountered reversible
cause of chronic anemia or worsening anemia in CKD
patients, other than anemia related directly to CKD, is iron
deficiency anemia.
Frequency of testing for anemia
1.1.1: For CKD patients without anemia (as defined below
in Recommendation 1.2.1 for adults and Recom-
mendation 1.2.2 for children), measure Hb concen-
tration when clinically indicated and (Not Graded):
K at least annually in patients with CKD 3
K at least twice per year in patients with CKD
4–5ND
K at least every 3 months in patients with CKD
5HD and CKD 5PD
1.1.2: For CKD patients with anemia not being treated
with an ESA, measure Hb concentration when
clinically indicated and (Not Graded):
K at least every 3 months in patients with CKD
3–5ND and CKD 5PD
K at least monthly in patients with CKD 5HD
[See Recommendations 3.12.1–3.12.3 for mea-
surement of Hb concentration in patients being
treated with ESA.]
RATIONALE
Relatively little is known about the development and
progression of anemia in patients with CKD. Consequently,
one cannot determine precisely the optimal frequency at
which Hb levels should be monitored. The recommendation
that patients with CKD be periodically evaluated for anemia
rests on observations that, in the absence of use of
erythropoiesis-stimulating agents (ESAs), there often is a
gradual decline in Hb over time in patients with CKD as the
level of glomerular filtration rate (GFR) declines,1 suggesting
the need for regular surveillance of Hb concentration. The
frequency of Hb monitoring, regardless of CKD stage, should
be influenced by the Hb level (i.e., more frequent monitoring
may be appropriate in patients with more severe anemia) and
rate of decline in Hb level. As kidney function declines and in
patients with more advanced CKD stages, the incidence and
prevalence of anemia increases. Thus, in order to identify
CKD patients who may need intervention with iron
administration, an ESA, or even require a transfusion,
more frequent monitoring of the Hb concentration will be
necessary at later CKD stages.
More frequent monitoring is recommended for adult
CKD 5HD and CKD 5PD patients with anemia who are not
receiving an ESA; at least monthly in CKD 5HD patients and
at least every 3 months in CKD 5PD patients. In CKD 5HD
patients, Hb monitoring is traditionally performed prior to a
mid-week hemodialysis (HD) session. While this is not
essential it probably does tend to minimize Hb variability due
to the longer inter-dialytic interval between the last treatment
of one week and the first of the next. As in all patients, Hb
testing should be performed whenever clinically indicated,
such as after a major surgical procedure, hospitalization, or
bleeding episode.
In the pediatric population with CKD, there is no direct
evidence to recommend a different frequency of monitoring
for anemia than for adults. In the Chronic Kidney Disease in
Children Prospective Cohort Study (CKiD), which evaluated
340 North American children with CKD using iohexol-
determined GFR,2 below a GFR threshold of 43ml/min per
1.73m2, there was a linear relationship between Hb and GFR,
with Hb 0.3 g/dl (3 g/l) lower per 5ml/min per 1.73m2 lower
GFR. Above that threshold, there was a nonsignificant
association of 0.1 g/dl (1 g/l) lower Hb for every 5ml/min
per 1.73m2 lower GFR. Because serum creatinine-based
estimated glomerular filtration rate (eGFR) using the
Schwartz formula may overestimate the true GFR in the
children3 providers need to consider the potential for
Hb decline and anemia even at early stages of CKD and
monitor accordingly. In children with CKD 5HD and
CKD 5PD, monthly monitoring for anemia is standard
clinical practice.
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Diagnosis of anemia
1.2.1: Diagnose anemia in adults and children 415 years
with CKD when the Hb concentration iso13.0 g/dl
(o130 g/l) in males and o12.0 g/dl (o120 g/l) in
females. (Not Graded)
1.2.2: Diagnose anemia in children with CKD if Hb
concentration is o11.0 g/dl (o110 g/l) in children
0.5–5 years, o11.5 g/dl (115 g/l) in children 5–12
years, and o12.0 g/dl (120 g/l) in children 12–15
years. (Not Graded)
RATIONALE
The Hb concentration values that define anemia and should
lead to initiation of an evaluation for the cause of anemia
are dependent on sex and age. The recommended Hb values
for adults and children represent the World Health
Organization (WHO) definition of anemia and establish a
benchmark for anemia workup that has been applied across
populations.4
An alternative source for Hb concentration values that
define anemia in children between 1 and 19 years is based on
US National Health and Nutrition Examination Survey III
(NHANES III) data from 1988–945 (Table 1). For children
between birth and 24 months, the data are taken from
normal reference values6 (Table 2).
These thresholds for diagnosis of anemia and evaluation
for the causes of anemia should not be interpreted as being
thresholds for treatment of anemia. Rather than relying on a
single laboratory test value, in patients without an apparent
cause for a low Hb level, the value should be confirmed to be
below the threshold values for diagnosis of anemia prior to
initiating a diagnostic work up.
Investigation of anemia
1.3: In patients with CKD and anemia (regardless of age
and CKD stage), include the following tests in initial
evaluation of the anemia (Not Graded):
K Complete blood count (CBC), which should
include Hb concentration, red cell indices, white
blood cell count and differential, and platelet count
K Absolute reticulocyte count
K Serum ferritin level
K Serum transferrin saturation (TSAT)
K Serum vitamin B12 and folate levels
RATIONALE
Complete blood count
The complete blood count (CBC) provides information
about the severity of anemia and adequacy of bone marrow
function. Severity of anemia is assessed best by measuring Hb
Table 1 | Hb levels in children between 1–19 years for initiation of anemia workupa
All races/ethnic
groups
Number of
subjects
Mean Hb
g/dl (g/l)
Standard deviation
g/dl (g/l)
Anemia definition met if value is
o5th percentile g/dl (g/l)
Boys
1 yr and over 12,623 14.7 (147) 1.4 (14) 12.1 (121)
1–2 yr 931 12.0 (120) 0.8 (8) 10.7 (107)
3–5 yr 1,281 12.4 (124) 0.8 (8) 11.2 (112)
6–8 yr 709 12.9 (129) 0.8 (8) 11.5 (115)
9–11 yr 773 13.3 (133) 0.8 (8) 12.0 (120)
12–14 yr 540 14.1 (141) 1.1 (11) 12.4 (124)
15–19 yr 836 15.1 (151) 1.0 (10) 13.5 (135)
Girls
1 yr and over 13,749 13.2 (132) 1.1 (11) 11.4 (114)
1–2 yr 858 12.0 (120) 0.8 (8) 10.8 (108)
3–5 yr 1,337 12.4 (124) 0.8 (8) 11.1 (111)
6–8 yr 675 12.8 (128) 0.8 (8) 11.5 (115)
9–11 yr 734 13.1 (131) 0.8 (8) 11.9 (119)
12–14 yrb 621 13.3 (133) 1.0 (10) 11.7 (117)
15–19 yrb 950 13.2 (132) 1.0 (10) 11.5 (115)
Hb, hemoglobin; yr, year.
aBased on NHANES III data, United States, 1988–94.5
bMenstrual losses contribute to lower mean and 5th percentile Hb values for group.
Table 2 | Hb levels in children between birth and 24 months
for initiation of anemia workupa
Age Mean Hb g/dl (g/l) 2 SDb g/dl (g/l)
Term (cord blood) 16.5 (165) 13.5 (135)
1–3 d 18.5 (185) 14.5 (145)
1 wk 17.5 (175) 13.5 (135)
2 wk 16.5 (165) 12.5 (125)
1 mo 14.0 (140) 10.0 (100)
2 mo 11.5 (115) 9.0 (90)
3–6 mo 11.5 (115) 9.5 (95)
6–24 mo 12.0 (120) 10.5 (105)
d, day; Hb, hemoglobin; mo, month; SD, standard deviation; wk, week.
aData taken from normal reference values. This was published in Nathan DG, Orkin
SH. Appendix 11: Normal hematologic values in children. In: Nathan DG, Orkin SH,
Ginsburg D et al. (eds). Nathan and Oski’s Hematology of Infancy and Childhood, 6th
edn. p 1841, & Elsevier, 2003.6
bValues 2 standard deviations below the mean are equivalent to o2.5th percentile.
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concentration rather than hematocrit. The latter measure-
ment is a relatively unstable analyte and its measurement
lacks standardization and is instrumentation dependent,
since it is derived indirectly by automated analyzers.7–9 There
is no evidence to support any different recommendation for
the initial evaluation of anemia for children compared to
adults.
In addition to Hb concentration, other reported results of
the CBC may convey important clinical information. The
anemia of CKD is hypoproliferative, and in general,
normochromic and normocytic. In this regard it is
morphologically indistinguishable from the anemia of
chronic disease.10 Folate or vitamin B12 deficiencies may
lead to macrocytosis, whereas iron deficiency or inherited
disorders of Hb formation (e.g., a- or b-thalassemia) may
produce microcytosis. Iron deficiency, especially if long-
standing, is associated with hypochromia (low mean
corpuscular hemoglobin [MCH]). Macrocytosis with leuko-
penia or thrombocytopenia suggests a generalized disorder of
hematopoiesis caused by toxins (e.g., alcohol), nutritional
deficit (vitamin B12 or folate deficiency), or myelodysplasia.
When these findings are present, further diagnostic evalua-
tion may be indicated.
The low erythropoietic activity that characterizes the
anemia of CKD is consistent with insufficient erythropoietin
stimulation. Erythropoietin levels are not routinely used in
distinguishing erythropoietin deficiency from other causes of
anemia in patients with CKD in most clinical settings and
their measurement is generally not recommended.11,12
Effective erythropoietic proliferative activity is most simply
assessed by determination of the absolute reticulocyte count.
Abnormalities of the white blood cell count and differential
or platelet count are not typical of the anemia of CKD and
should prompt investigation for other processes.
Reticulocyte count, which may be obtained with auto-
mated CBC testing, may be high in patients who have active
blood loss or hemolysis, and may be low in hypoproliferative
erythropoiesis with anemia.
Iron status
There are two important and distinct aspects of the
assessment of iron status testing: the presence or absence of
storage iron and the availability of iron to support ongoing
erythropoiesis. The serum ferritin is the most commonly
used test for evaluation of storage iron, for which the ‘gold
standard’ remains examination of a bone marrow aspiration
stained for iron.13 The transferrin saturation (TSAT; serum
iron 100 divided by total iron binding capacity) is the most
commonly used measure of the availability of iron to support
erythropoiesis. The serum ferritin is affected by inflammation
and is an ‘acute phase reactant’13 and, thus, ferritin values
have to be interpreted with caution in CKD patients,
especially those on dialysis in whom subclinical inflammation
may be present.14
Serum ferritin values r30 ng/ml (r30 mg/l) indicate
severe iron deficiency and are highly predictive of absent
iron stores in bone marrow.15,16 Ferritin values 430 ng/ml
(430 mg/l), however, do not necessarily indicate the presence
of normal or adequate bone marrow iron stores. Studies
assessing ferritin levels above which all or nearly all patients
with CKD have normal bone marrow iron stores have
produced varied results but most CKD patients, including
those who are on HD, will have normal bone marrow iron
stores when their serum ferritin level is Z300 ng/ml
(Z300 mg/l). Even at serum ferritin levels of 100 ng/ml
(100 mg/l) most CKD patients have stainable bone marrow
iron stores.16–21 As will be discussed in Chapter 2, the serum
ferritin and TSAT values are often used together to assess iron
status, diagnose iron deficiency, and predict an erythropoietic
response to iron supplementation (Supplementary Table 1
online).
Other tests of iron status, such as percentage of
hypochromic red blood cells and reticulocyte Hb content
may be used instead of, or in addition to, TSAT and ferritin
levels if available. Measurement of hepcidin levels has not
been shown to be clinically useful or superior to more
standard iron status tests in patients with CKD.22,23
Vitamin B12 and folate
Folate and vitamin B12 deficiency are uncommon but
important causes of treatable anemia, typically associated
with macrocytic red blood cell (RBC) indices. Limited data
indicate a prevalence of vitamin B12 and folate deficiency in
r10% of HD patients; the prevalence in CKD patients
is not known. Nonetheless, since these deficiencies are easily
correctable, and in the case of vitamin B12 may indicate
other underlying disease processes, assessment of folate
and vitamin B12 levels are generally considered standard
components of anemia evaluation, especially in the
presence of macrocytosis. Folate deficiency is best detected
in most patients with serum folate level testing; RBC folate
levels can be measured when serum folate levels are equivocal
or when there is concern that recent dietary intake may
obscure underlying folate deficiency using serum levels
alone.24
Additional tests
Other tests, in addition to those indicated above, may be
appropriate in individual patients and in certain specific
clinical settings. For instance measurement of high sensitivity
C-reactive protein (CRP) may be indicated if occult
inflammation is a concern. In certain countries and/or in
patients of specific nationalities or ethnicities, testing for
hemoglobinopathies, parasites, and other conditions may be
appropriate.
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